Ind-Swift Laboratories Ltd.

₹385.35

7.9 (2.1%)

INDSWFTLAB Share Price

Pharmaceuticals & Biotechnology

As on September 11, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 3,351 Cr

P/E Ratio10.58

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	381.68	Bullish
10-DMA	373.69	Bullish
20-DMA	356.1	Bullish
50-DMA	285.9	Bullish
100-DMA	221.21	Bullish
200-DMA	169.9	Bullish

Historical Performance

1 Year

255.8%

3 Years

312.4%

5 Years

442.7%

10 Years

898.3%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	5,617	12,809	12,073	10,387	8,913
Total Expenditure	5,811	10,267	9,781	8,431	7,085
Other Income	814	454	335	435	227
Operating Profit	620	2,996	2,627	2,391	2,055
Interest	29	511	922	955	1,002
Depreciation	245	533	574	1,310	873
Profit Before Tax	2,578	5,818	865	125	180
Consolidated Net Profit	2,505	4,210	476	-21	-31
Adjusted EPS	36	71	8	---	-1

Compounded Sales Growth

10 Years:-3

5 Years:-6.3

3 Years:-11.6

TTM:-15.2

Compounded Profit Growth

10 Years:8.1

5 Years:32.6

3 Years:109.5

TTM:-9.9

Stock Price CAGR

10 Years:26.1

5 Years:40.8

3 Years:61.8

TTM:265

Return on Equity

10 Years:-14.3

5 Years:-0.5

3 Years:8.1

last year:36.4

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	687	591	598	598	598
Total Reserves	10,302	8,724	6,221	5,412	5,437
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	2	-195	7,412	8,136	8,402
Other Current Liabilities	988	228	1,057	891	813
Short Term Borrowings	56	27	492	640	934
Total Liabilities	13,937	11,332	17,942	17,489	17,581
Capital Work in Progress	---	---	77	93	107
Long Term Loans & Advances	813	3,539	42	40	61
Currents Investments	394	---	---	---	---
Short Term Loans and Advances	1,153	496	1,920	1,516	659
Total Current Assets	8,653	6,611	11,631	10,733	9,419
Total Assets	13,937	11,332	17,942	17,489	17,581
Adjusted Book Value	160	158	84	68	66

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 10.58, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a strong 3-year price CAGR of 61.8%, indicating sustained price appreciation.
The stock carries a beta of 0.8, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹620 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹5617 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 3647075.5

No. of Shares: 9464 (Approx)

Performance:264.7%

2647075.5

NIFTY Performance: -6.8%

1 day Top Gainers